ONO PHARMACEUTICAL

Osaka, Japan Founded: 1947 • Age: 79 yrs
RD company focused on manufacturing of drugs for multiple therapeutic areas
Annual revenue $3.3B Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About ONO PHARMACEUTICAL

ONO PHARMACEUTICAL is a company based in Osaka (Japan) founded in 1947. ONO PHARMACEUTICAL has completed 1 acquisition, including Deciphera. ONO PHARMACEUTICAL operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.

  • Headquarter Osaka, Japan
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Ono Pharmaceutical Co., Ltd.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $3.26 B (USD)
    -3.14
    as on Mar 31, 2025
  • Net Profit
    $334.93 M (USD)
    -60.89
    as on Mar 31, 2025
  • EBITDA
    $604.15 M (USD)
    -50.32
    as on Mar 31, 2025
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of ONO PHARMACEUTICAL

ONO PHARMACEUTICAL is a publicly listed company on the TSE with ticker symbol 4528 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TSE · Ticker: 4528 · Sector: Health technology · Japan

People of ONO PHARMACEUTICAL

Headcount 1000-5000
Employee Profiles 18
Employee Profiles
People
Kunihiro Nakano
Senior Director, Asian Business Department
People
Yasunori Ninomiya
Head Of Global Marketing
People
Masao Akamatsu
Associate Director, Business Development, Corporate Development & Strategy
People
Tomohiro H.
Corporate Communications

Unlock access to complete

Funding Insights of ONO PHARMACEUTICAL

Premium access

Detailed funding history for ONO PHARMACEUTICAL

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ONO PHARMACEUTICAL

ONO PHARMACEUTICAL has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Deciphera.

Investments
Premium access

Investment portfolio details for ONO PHARMACEUTICAL

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Type 2 kinase inhibitors for cancer treatment are developed.
Locked Locked 2003 Locked
Premium access

Complete acquisition details for ONO PHARMACEUTICAL

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - ONO PHARMACEUTICAL

Premium access

Detailed financials for ONO PHARMACEUTICAL

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ono Pharmaceutical Comparisons

ONO PHARMACEUTICAL Primary company
Description
R&D company focused on manufacturing of drugs for multiple t...
Location
Osaka, Japan
Founded Year
1947
Annual Revenue
$3.26 B (USD)
Net Profit
$334.93 M (USD)
EBITDA
$604.15 M (USD)
Employees
Not available
Premium access

Peer comparison for ONO PHARMACEUTICAL

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ONO PHARMACEUTICAL

ONO PHARMACEUTICAL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Pharmaceutical products are manufactured and marketed worldwide.
Locked Locked Locked
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
Locked Locked Locked
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
Locked Locked Locked
Traditional pharmaceutical medicines are developed for multiple health fields.
Locked Locked Locked
Developer of drugs for the treatment of multiple disorders
Locked Locked Locked
Biopharmaceutical research and drug development are conducted globally by AbbVie.
Premium access

Detailed competitors of ONO PHARMACEUTICAL

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ono Pharmaceutical

Premium access

Complete news archive for ONO PHARMACEUTICAL

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ONO PHARMACEUTICAL

ONO PHARMACEUTICAL was founded in 1947.

ONO PHARMACEUTICAL is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.

Annual revenue of ONO PHARMACEUTICAL is $3.26B as on Mar 31, 2025.

ONO Pharmaceutical was established in 1947 in Osaka, Japan, as a research and development entity within the pharmaceutical sector. Operations center on the production of medications targeting various therapeutic areas, including immunology and oncology. Services encompass drug discovery, clinical trials, and global distribution, with headquarters maintained in Japan and international partnerships facilitated.

ONO PHARMACEUTICAL's top competitors include Merck, Roivant Sciences and AbbVie.

Yes, ONO PHARMACEUTICAL is publicly traded on TSE under the ticker symbol 4528.

ONO PHARMACEUTICAL has made 1 acquisition, including Deciphera.

The ticker symbol of ONO PHARMACEUTICAL is 4528 on TSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available